证券代码：600511 证券简称：国药股份 公告编号：2025-041 国药集团药业股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 12 月 9 日 (二)股东会召开的地点：北京市东城区永定门西滨河路 8 号院 7 楼中海地产广场 西塔 8 层会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 228 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 466,351,992 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 61.8091 | (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由董事会召集，董事长刘月涛主持本次会议，会议采用现场投票和网络 投票的方式进行表决，符合《公司法》及《 ...

二、 董事会会议审议情况 本次会议审议并通过了如下决议： （一）以 9 票同意、0 票反对和 0 票弃权的结果审议通过《国 药股份关于调整第八届董事会专门委员会委员的议案》。 证券代码：600511 证券简称：国药股份 公告编号：临 2025-042 国药集团药业股份有限公司 第八届董事会第三十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 一、 董事会会议召开情况 国药集团药业股份有限公司（以下简称"公司"或"国药股 份"）第八届董事会第三十三次会议通知及资料于 2025 年 11 月 28 日以书面、电子邮件等形式发出，会议于 2025 年 12 月 9 日以 现场结合通讯表决方式召开。本次会议应到董事九名，实到董事 九名，其中四名独立董事参加了会议，董事长刘月涛先生主持本 次会议，部分高管列席会议，符合《公司法》和《公司章程》的 有关规定。 为加强董事会建设，提高董事会决策的科学性，充分发挥专 1 门委员会在上市公司治理中的作用，公司拟调整第八届董事会战 略委员会、提名委员会、审计委员会、薪酬与考核委 ...

Core Viewpoint - The report highlights the growth and trends in the Chinese pharmaceutical manufacturing outsourcing (CMO/CDMO) industry, indicating a slight increase in the number of enterprises in the sector from the previous year [1]. Industry Summary - As of January to October 2025, the number of pharmaceutical manufacturing enterprises reached 9,846, an increase of 98 enterprises compared to the same period last year, representing a year-on-year growth of 1.01% [1]. - The pharmaceutical manufacturing sector accounts for 1.88% of the total industrial enterprises in China [1]. Company Summary - The report mentions several listed companies in the pharmaceutical sector, including Guoyao Modern (600420), Kunming Pharmaceutical Group (600422), and others, indicating their relevance in the industry landscape [1]. - The data is sourced from the National Bureau of Statistics and organized by Zhiyan Consulting, a leading industry consulting firm in China [1].

Core Insights - The pharmaceutical manufacturing industry in China is projected to see an increase in export value, with a reported export value of 17.74 billion yuan in October 2025, reflecting a year-on-year growth of 2.9% [1] - Cumulatively, from January to October 2025, the total export value reached 195.22 billion yuan, marking a year-on-year increase of 12.1% [1] Company Insights - Listed companies in the pharmaceutical sector include: Guoyao Modern (600420), Kunming Pharmaceutical Group (600422), Pian Zai Huang (600436), Qianjin Pharmaceutical (600479), Tianyao Pharmaceutical (600488), Guoyao Shares (600511), Lianhuan Pharmaceutical (600513), Hefei China (603122), Kanghui Pharmaceutical (603139), Shapuaisi (603168), Aoxiang Pharmaceutical (603229), and Daclin (603233) [1] Industry Report - The report titled "Market Development Trends and Strategic Assessment of China's Pharmaceutical Manufacturing Industry from 2025 to 2031" was published by Zhiyan Consulting, indicating a focus on the future growth and strategic direction of the industry [1][2] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, providing comprehensive industry research reports and tailored consulting services [2]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has officially responded to the long-standing call from pharmaceutical companies to separate medical insurance payment standards from drug prices, allowing companies to independently report and register innovative drug prices [1][9]. Group 1: Announcement and Implementation - On December 2, the NHSA issued an announcement regarding the establishment of a drug price registration and inquiry service, enabling companies to self-report innovative drug prices with relevant transaction proofs and a commitment to price authenticity [1][9]. - The newly launched Chinese drug registration system allows companies to independently declare prices, which will not be subject to review by the NHSA, provided that companies can prove the authenticity of the prices through transaction evidence [3][11]. Group 2: Pricing Mechanism - The registration price will be independent of the medical insurance network price, meaning that the medical insurance payment standard is no longer the sole reference for drug pricing in the domestic market [2][10]. - The registration price will serve as a "market price" reflecting real transaction values, granting companies significant autonomy in pricing, which is expected to facilitate the construction of a global pricing system for innovative drugs [2][10]. Group 3: Market Dynamics - The separation of registration prices from medical insurance prices establishes two independent pricing mechanisms, allowing for a clearer distinction between market prices and insurance payment standards [5][13]. - The new system is expected to enhance the negotiation position of domestic innovative drug companies in international markets, as it provides a credible market price that can be used in negotiations with foreign healthcare systems [14][15]. Group 4: Global Market Acceptance - There is optimism regarding the acceptance of the registration price as a market price in global markets, particularly as the Chinese market is characterized by high price transparency [6][13]. - The registration price must reflect actual transaction prices, which may still differ significantly from higher prices in markets like the United States, but it is seen as a step towards aligning with international pricing mechanisms [6][14]. Group 5: Implications for Foreign Companies - The new pricing mechanism is also significant for foreign pharmaceutical companies, as it alleviates concerns that domestic pricing could adversely affect global pricing strategies during negotiations with the NHSA [8][15]. - The establishment of a dual pricing system is expected to encourage foreign companies to enter the Chinese market without the fear that domestic negotiations will impact their global pricing structures [8][15].

Core Viewpoint - The launch of the China Drug Price Registration System marks a significant step towards a globalized pricing framework for innovative drugs, enhancing market-oriented pricing capabilities for pharmaceutical companies and supporting the development of a new pricing ecosystem that aligns drug prices with innovation value and market demand [1][2][6]. Group 1: Drug Price Registration System - The new system allows domestic and international pharmaceutical companies to independently register drug prices, ensuring accountability for price authenticity [1][3]. - The system operates under the principle of "one location acceptance, nationwide sharing, global openness," and is managed by a state-owned enterprise in Beijing [1][3]. - The first batch of companies to register prices includes major players such as China National Pharmaceutical Group, Beijing Tongrentang, and Roche, indicating strong industry participation [3]. Group 2: Impact on Pharmaceutical Industry - The system is expected to enhance the pricing strategies of pharmaceutical companies, allowing them to adjust prices based on clinical value, supply-demand dynamics, and competitive landscape [3][4]. - The dual mechanism of registration and query will promote transparency in drug pricing, moving away from previous opaque practices [4]. - The establishment of this system is anticipated to create a comprehensive pricing structure that encompasses innovative drugs, insurance payment prices, and generic drug prices, benefiting the innovative drug sector [5]. Group 3: Global Market Development - The China Drug Price Registration System is designed to facilitate the international expansion of Chinese innovative drugs and attract high-quality foreign drugs into the Chinese market [2][5]. - Data indicates that the total amount of overseas licensing transactions by Chinese pharmaceutical companies exceeded $92 billion in the first three quarters of 2025, highlighting the growing global presence of Chinese innovative drugs [2]. - The system aims to address significant price discrepancies between domestic and international markets, influenced by factors such as currency exchange rates and pricing mechanisms [5]. Group 4: Long-term Industry Implications - The implementation of the drug price registration system is expected to enhance the global competitiveness of China's biopharmaceutical industry and drive high-quality innovation within the sector [6].

Group 1 - The core viewpoint of the article is that He Yuan Bio has established a commercial partnership with China National Pharmaceutical Group (Sinopharm) and other distributors to enhance its market presence and product promotion [1] - He Yuan Bio has signed distribution agreements with multiple pharmaceutical distributors, including Sinopharm and Betta Pharmaceuticals, completing a sales network layout across over 30 provinces and cities in China [1] - Sinopharm acts as a commercial partner for He Yuan Bio in specific regions, focusing on academic promotion, market expansion, and channel development to jointly enhance product market coverage and clinical application [1]

Group 1 - The core viewpoint of the article highlights the collaboration between He Yuan Bio and China National Pharmaceutical Group (Sinopharm) as a commercial partner in specific regions, focusing on product promotion and market expansion [1] - He Yuan Bio has established a sales network across more than 30 provinces and cities in China through agreements with multiple distributors, including Sinopharm and Betta Pharmaceuticals [1] - The company is actively engaged in academic promotion, market development, and channel construction with Sinopharm to enhance product market coverage and clinical application [1]

Core Viewpoint - The establishment of the China Drug Price Registration System (China Drug Registration) aims to create a global drug pricing system, support the high-quality development of innovative drugs, and enhance the integration of China's pharmaceutical industry into international competition [1][4]. Group 1: Announcement and Implementation - The National Healthcare Security Administration (NHSA) and the Beijing Municipal Government jointly launched the China Drug Registration, providing a platform for drug price registration and inquiry services [3]. - The registration will initially focus on innovative drugs and gradually expand to other drugs, allowing pharmaceutical companies to self-declare prices while ensuring the authenticity of the information [3][5]. Group 2: Independence and Pricing Mechanism - China Drug Registration operates independently from provincial medical procurement platforms, ensuring that registered prices do not alter the pricing levels for insured and uninsured patients [5][6]. - The registration system allows for the disclosure of market prices, which can be used for international price comparisons, enhancing the competitiveness of Chinese pharmaceutical companies in the global market [6][7]. Group 3: Global Market Integration - The establishment of China Drug Registration facilitates the "going out" strategy for Chinese innovative drugs and attracts high-quality foreign drugs into the Chinese market [7][8]. - The system supports Chinese companies in gaining global market recognition and establishing international brand influence, which is crucial for their valuation and future research and development [7]. Group 4: Participation of Foreign Companies - The first batch of registered companies includes both domestic and foreign pharmaceutical firms, indicating a collaborative approach to enhance the availability of innovative drugs in China [8]. - The independent pricing mechanism of China Drug Registration is expected to attract multinational pharmaceutical companies to participate in national healthcare negotiations, thereby increasing the availability of innovative drugs in the Chinese market [8].

（原标题：利好创新药！中国药品价格登记系统上线） 21世纪经济报道记者 闫硕 北京报道 创新药全链条发展已进入全面推进阶段，国家医保局聚焦价格登记查询环节，推出全新支持政策。 12月2日，中国药品价格登记系统上线。国内外医药企业可根据发展需要，自主申报登记药品价格,并为价格真实性负责。药品价格登记按照"一地 受理、全国共享、全球公开"原则，采取社会化运营模式，由北京市西城区国资企业负责运营，对外提供登记、查询等服务。 近年来，我国医药产业创新动能持续释放，创新能力显著增强。一批具备自主特色、达到国际先进水平的创新药相继问世，既为国内患者带来全 新治疗选择与康复希望，也为中国医药企业拓展全球市场奠定了坚实基础。 市场数据直观印证了中国创新药的全球化发展势头。据统计，2025年前三季度，我国医药企业海外授权交易总金额突破920亿美元。随着中国创新 药在全球市场的参与度不断提升，其终端价格的国际参考作用日益凸显。 这一趋势既彰显了中国超大市场规模在全球医药领域的重要地位，也对我国医药价格体系的完善提出了更高要求。在此背景下，国家医保局借鉴 国际通行做法，牵头建设中国药品价格登记系统。 该系统主要包含两大服务，即药品 ...